tiprankstipranks
Trending News
More News >
TNL Mediagene (TNMG)
NASDAQ:TNMG
US Market
Advertisement

TNL Mediagene (TNMG) AI Stock Analysis

Compare
20 Followers

Top Page

TNMG

TNL Mediagene

(NASDAQ:TNMG)

Select Model
Select Model
Select Model
Underperform 38 (OpenAI - 4o)
Rating:38Underperform
Price Target:
$0.50
▲(78.57% Upside)
TNL Mediagene's overall stock score is primarily impacted by its poor financial performance, which includes severe profitability and cash flow challenges. The technical analysis further supports a bearish outlook, with the stock trading below key moving averages and indicators suggesting oversold conditions. The negative P/E ratio and lack of dividend yield highlight valuation concerns, making the stock less attractive to investors.
Positive Factors
Revenue Growth
The company has achieved a significant revenue growth rate of 35.08%, indicating strong market demand and effective business strategies that could support long-term expansion.
Digital Asset Strategy
The integration of digital assets into the business model could enhance financial flexibility and open new revenue streams, aligning with industry trends and potentially boosting future growth.
Strategic Partnerships
Partnerships with tech and media firms enhance TNMG's offerings and expand revenue opportunities, providing a competitive edge and supporting sustainable growth.
Negative Factors
Profitability Issues
Severe profitability issues with negative margins highlight operational inefficiencies, posing risks to financial stability and long-term viability.
Cash Flow Challenges
Negative cash flow metrics indicate struggles in generating cash from operations, raising concerns about liquidity and the ability to fund future growth.
High Leverage
High leverage with a debt-to-equity ratio of 63.6% suggests financial risk, limiting flexibility and potentially impacting long-term financial health.

TNL Mediagene (TNMG) vs. SPDR S&P 500 ETF (SPY)

TNL Mediagene Business Overview & Revenue Model

Company DescriptionTNL Mediagene engages in digital advertising, integrated marketing, marketing survey, artificial intelligence technology, data analysis, content service platform, and production of audio-visual programs. It operates media, technology, and digital studio businesses primarily in Japan and Taiwan.
How the Company Makes MoneyTNL Mediagene makes money primarily through multiple revenue streams, including digital advertising, subscription services, and content licensing. The company's digital advertising revenue is generated by partnering with brands to offer targeted advertising solutions across its platforms, utilizing data-driven insights to maximize reach and engagement. Subscription services provide a steady income stream, as readers pay for premium content and exclusive features. Additionally, TNMG licenses its content to other media outlets and platforms, further expanding its reach and monetization potential. Strategic partnerships with technology firms and media companies also play a crucial role in enhancing TNMG's offerings and expanding its revenue opportunities.

TNL Mediagene Financial Statement Overview

Summary
TNL Mediagene is facing significant financial challenges, including negative EBIT and net profit margins, suggesting operational inefficiencies and risks in sustaining growth. The high debt-to-equity ratio and negative cash flow further highlight financial instability.
Income Statement
20
Very Negative
TNL Mediagene's income statement reveals significant challenges. The company has experienced a rapid increase in total revenue year-over-year, with a notable increase of 35.3% in 2024 compared to 2023. However, this growth is overshadowed by substantial losses, exemplified by a negative EBIT margin of -157.4% and a net profit margin of -175.3% for 2024. The company faces profitability issues, which are further highlighted by negative EBITDA and net income, indicating operational inefficiencies and potential risks in sustaining growth.
Balance Sheet
30
Negative
The balance sheet of TNL Mediagene highlights a mixed financial position. While the company has managed to maintain a positive stockholders' equity in 2024, the debt-to-equity ratio is concerning at 63.6%, suggesting high leverage. The equity ratio stands at 39.2%, indicating moderate reliance on equity financing. However, the return on equity is negative due to consistent net losses, raising concerns about the company's ability to generate returns for shareholders.
Cash Flow
15
Very Negative
TNL Mediagene's cash flow statement underscores substantial cash management issues. The operating cash flow is negative, reflecting challenges in generating sufficient cash from operations. The company has a negative free cash flow growth rate, exacerbating liquidity concerns. Additionally, the free cash flow to net income ratio is unfavorable, indicating that the company struggles to convert its net income into positive cash flow, raising red flags about its financial health.
BreakdownDec 2024Dec 2023Dec 2022
Income Statement
Total Revenue48.49M35.84M20.01M
Gross Profit17.74M12.65M7.74M
EBITDA-73.92M1.33M-10.01M
Net Income-85.00M-804.98K-11.01M
Balance Sheet
Total Assets92.92M119.62M26.53M
Cash, Cash Equivalents and Short-Term Investments3.65M3.03M3.91M
Total Debt23.14M17.59M6.71M
Total Liabilities56.51M47.25M50.67M
Stockholders Equity36.40M72.62M-25.30M
Cash Flow
Free Cash Flow-10.30M-1.68M-1.04M
Operating Cash Flow-10.21M-1.42M-760.11K
Investing Cash Flow947.95K252.74K-2.36M
Financing Cash Flow10.00M530.97K4.99M

TNL Mediagene Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
47
Neutral
2.07M>-0.01-44.99%6.77%97.28%
45
Neutral
4.10M-0.100.00%-100.00%86.75%
38
Underperform
-155.94%35.08%-10462.99%
30
Underperform
2.20M-0.090.00%0.00%74.27%
29
Underperform
2.18M-0.040.00%0.00%98.25%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TNMG
TNL Mediagene
0.28
-15.28
-98.20%
BDRX
Biodexa Pharmaceuticals
6.61
-61.84
-90.34%
SLRX
Salarius Pharmaceuticals
4.32
-20.28
-82.44%
LGMK
LogicMark
0.01
-3.84
-99.74%
BJDX
Bluejay Diagnostics
1.46
-5.68
-79.55%
STSS
Sharps Technology, Inc.
8.16
-1,132.32
-99.28%

TNL Mediagene Corporate Events

TNL Mediagene Announces Board Changes in July 2025
Jul 23, 2025

On June 30, 2025, TNL Mediagene announced the resignation of Ms. Takako Masai from its Board of Directors for personal reasons, with no disagreements with the company’s operations. Subsequently, Ms. Naoko Okumoto was appointed as an interim director effective July 1, 2025, bringing extensive experience in tech investment and cross-border business development. Her appointment is expected to enhance the company’s strategic insight and global perspective, pending shareholder approval at the upcoming annual meeting.

TNL Mediagene Amends Share Purchase Agreement with Tumim Stone Capital
Jun 16, 2025

TNL Mediagene, a company involved in media and technology, has announced amendments to its ordinary share purchase agreement with Tumim Stone Capital LLC, originally dated November 25, 2024. On June 13, 2025, the amendments removed the requirement that the closing sale price of TNL Mediagene’s ordinary shares must be at least $1.00 per share. Following this amendment, TNL Mediagene issued a purchase notice to Tumim for 440,000 ordinary shares, expected to be issued around June 20, 2025. This strategic move aims to enhance the company’s financial flexibility and market positioning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 19, 2025